Arcus Biosciences RCUS Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $247M-4.3% | $258M+121% | $117M+4.5% | $112M-70.8% | ||
| $523M+16.7% | $448M+31.8% | $340M+18.1% | $288M+12.1% | ||
| $110M-8.3% | $120M+2.6% | $117M+12.5% | $104M+44.4% | ||
| $633M+7.7% | $588M+28.7% | $457M+16.6% | $392M+19.1% | ||
| $633M+7.7% | $588M+28.7% | $457M+16.6% | $392M+19.1% | ||
| -$386M-17.0% | -$330M+2.9% | -$340M-21.4% | -$280M-619% | ||
| -156.3%-28.4pp | -127.9%+163pp | -290.6%-40.6pp | -250%-264pp | ||
| $8M+100% | $4M— | —— | $2M— | ||
| $33M-31.3% | $48M+23.1% | $39M+175% | $14.19M+1,319% | ||
| -$353M-25.2% | -$282M+6.3% | -$301M-13.2% | -$266M-584% | ||
| $0-100% | $1M-83.3% | $6M+500% | $1M-50.0% | ||
| -$353M-24.7% | -$283M+7.8% | -$307M-15.0% | -$267M-604% | ||
| -142.9%-33.2pp | -109.7%+153pp | -262.4%-24.0pp | -238.4%-252pp | ||
| -$3.31-6.8% | -$3.10+25.3% | -$4.15-11.6% | -$3.72— | ||
| -$3.31-6.8% | -$3.10+25.3% | -$4.15-11.6% | -$3.72— | ||
| 418.8M+16.7% | 358.8M+21.7% | 294.8M+2.6% | 287.2M+2.2% | ||
| 418.4M+16.6% | 358.8M+21.7% | 294.8M+2.6% | 287.2M— | ||
| $41M-21.2% | $52M+26.8% | $41M+147% | $16.58M+1,558% | ||
| -$386M-17.0% | -$330M+2.9% | -$340M-21.4% | -$280M-619% | ||
| -$376M-17.5% | -$320M+3.6% | -$332M-21.2% | -$274M-572% | ||
| -$376M-17.5% | -$320M+3.6% | -$332M-21.2% | -$274M-572% | ||
| -152.2%-28.2pp | -124%+160pp | -283.8%-39.1pp | -244.6%-260pp | ||
| -$386M-17.0% | -$330M+2.9% | -$340M-21.4% | -$280M-619% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Arcus Biosciences's revenue?
- Arcus Biosciences (RCUS) generated $236.0M in revenue over the trailing twelve months, up 67.4% year over year.
- Is Arcus Biosciences profitable?
- Arcus Biosciences is not currently profitable: it reported a net loss of $369.0M over the trailing twelve months, a -156.4% net margin.
- What is Arcus Biosciences's earnings per share?
- Arcus Biosciences's diluted EPS over the trailing twelve months is $-3.19.
- Where does Arcus Biosciences's income statement data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
